Review
Copyright ©The Author(s) 2022.
World J Diabetes. Jan 15, 2022; 13(1): 5-26
Published online Jan 15, 2022. doi: 10.4239/wjd.v13.i1.5
Table 1 Incidence of dysglycemia in women with polycystic ovary syndrome
Ref.
Sample size
Country
PCOS criteria
T2D criteria
Age (yr)
BMI (kg/m2)    
IFG (%)
IGT (%)
T2D (%)
Rajkhowa et al[142], 1996 90UKNIHWHO26 (15-39)31.6 (18-48)?92
Legro et al[61], 1999 254USANIHWHO14-4432 ± 3?317.5
Ehrmann et al[62], 1999 122USANIHADA25 ± 0.7 (13-40)30-4393510
Gambineri et al[3], 2004 121ItalyRotterdamWHO14-3720-38?15.72.5
Legro et al[143], 2005 71USANIHADA30 ± 629 ± 6.4?2510
Chen et al[144], 2006 102ChinaRotterdamWHO24.2 ± 621.7 ± 4?20.51.9
Mohlig et al[64], 2006 264GermanyNIHWHO28 ± 0.430 ± 0.4?14.31.5
Vrbikova et al[145], 2007 244Czech RepublicRotterdamADA27 ± 7.527 ± 6.912.39.41.6
Gagnon et al[146], 2007 105CanadaNIHADA28.3 (14-47)35.5 (19-54)?235
Dabadghao et al[63], 2007 372AustraliaRotterdamADA30 ± 5 (15-62)35 ± 8315.64
Espinos-Gomez et al[147], 2008 102SpainNIHWHO26 ± 630.2 ± 8?10.77.7
Cheung et al[148], 2008 295ChinaRotterdamADA30 ± 625 ± 5.99.210.57.5
Bhattacharya et al[149], 2009 264IndiaRotterdamWHO24 ± 427 ± 4.5?14.4
Seneviratne et al[15], 2009 168Sri LankaRotterdamWHO29 ± 4 (20–40)25.92 (16-39)?23.210.1
Lee et al[50], 2009 194Korea RotterdamADA27 ± 524 ± 4171
Wei et al[51], 2009 356China RotterdamWHO32 ± 4 (19-44)22 ± 4.2?7.63,1
Zhao et al[150], 2010818ChinaRotterdamADA25 ± 5?8.535.44
Stovall et al[151], 2011 78USANIHADA26 ± 6.429 ± 6 (18-43)214?
Celik et al[66], 2013 252TurkeyRotterdamADA24 ± 526 ± 5.7?14.32
Veltman-Verhulst et al[21], 2013 226NetherlandsRotterdamADA29.6 ± 427 ± 6.72143.5
Lerchbaum et al[152], 2014 714AustriaRotterdamADA27 (23-32)24.2 (21-30)12.81.5
Vrbikova et al[145], 2014 330Czech RepublicRotterdamADA27.8 ± 727.6 ± 6128.83
Amato et al[22], 2015 241ItalyRotterdamWHO24 ± 6 (14-43)30 ± 6 (18-50)11.65.41.7
Ganie et al[14], 2015 2014IndiaRotterdamADA23 ± 5.425 ± 4.414.55.96.3
Gracelyn et al[153], 2015 200IndiaRotterdamADA16-40??14.51.5
Li et al[154], 2016 2436ChinaRotterdamADA2721.5613.519.83.9
Ollila et al[127], 2017 265FinlandRotterdamWHO4628.6 ± 6??12.4
Pelanis et al[13], 2017 876SwedenRotterdamADA29 (25-34)28 (23-33)11123
Zhang et al[19], 2018 378ChinaRotterdamIDF27 ± 4.430 ± 4.331.58.7
Ortiz-Flores et al[155], 2019 400SpainRotterdamWHO26 (14-49)28.6 (22-34)1414.52.5
Table 2 Guidelines regarding oral glucose tolerance test upon diagnosis of Polycystic ovary syndrome
Ref.
OGTT recommended upon diagnosis in all women with PCOS
Follow-up with OGTT
Joint AACE/ACE and AE-PCOS society[56]Yes(1) Yearly in women with IGT; and (2) Every 1–2 years based on BMI (not specified) and family history of T2D
Australian NHMRC[57]Recommended if one or more criteria exist: (1) BMI > 25 kg/m2 or in Asians > 23 kg/m2; (2) History of IFG, IGT, GDM; (3) Family history of T2D; (4) Arterial hypertension; and (5) High-risk ethnicityEvery 1-3 years, based on presence of other diabetesrisk factors
Endocrine Society[55]YesEvery 3–5 years (Sooner if additional risk factors for T2D develop)
Royal College of Obstetricians andGynecology[59]Recommended if one or more criteria exist: (1) BMI ≥ 25 kg/m2; (2) Age ≥ 40 years; (3) Previous GDM; and (4) Family history of T2DYearly in women with IGT or IFG
AE-PCOS Society[58]Recommended if one or more criteria exist: (1) BMI ≥ 30 kg/m2; (2) Age ≥ 40 years; (3) Previous GDM; and (4) Family history of T2DEvery 2 years in women with risk factors (Sooner if additional risk factors for T2D develop)
ESHRE and ASRM[60]Recommended if BMI ≥ 27 kg/m2Not specified